论文信息 - The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations - 字舞流文

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

C. Bloomfield | K. Döhner | R. Schlenk | H. Döhner | A. Ganser | R. Larson | J. Sierra | S. Mandrekar | F. Appelbaum | D. Niederwieser | M. Tallman | R. Stone | A. Wei | M. Sanz | G. Marcucci | H. Serve | S. Geyer | G. Ehninger | J. Brandwein | J. Krauter | C. Thiede | S. Amadori | T. Witte | F. Coco | R. Klisovic | B. Medeiros | B. Sanford | K. Laumann